
Bio-Techne Net Sales Rise 2% to $1.159 Billion Amid Acquisition Growth
Bio-Techne CorporationDescription
What this story covers
Bio-Techne's fiscal 2024 10-K reports 2 percent net sales growth to 1 point 159 billion dollars, driven by Diagnostics and Genomics gains and Lunaphore acquisition, despite Protein Sciences headwinds. Adjusted EPS 1 dollar 77 cents, solid liquidity with 299 million dollars operating cash flow, but faces economic, regulatory, and integration risks.
Story snapshot
CompanyBio-Techne Corporation
TickerTECH
VariantStandard detailed
Duration21:16
Filing type10-K
PeriodAnnual 2024
IndustryHealthcare & Pharmaceuticals
Accession0001558370-24-012430
Full Story Script
Content not available for this story.